A powerful new treatment has emerged in efforts to reduce high cholesterol levels and the associated risk of heart health problems. In a new trial, the drug enlicitide decanoate was found to lower 'bad' cholesterol by almost 60 percent.

An international research team tested the drug in a randomized clinical trial involving people with an inherited condition that causes dangerously high blood levels of low-density lipoprotein cholesterol (LDL-C) – the 'bad' type.

"Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder that affects approximately 1 in 250 individuals and is characterized by elevated levels of LDL-C from birth," write the researchers in their published paper.

They recruited 293 participants with HeFH, who were already taking cholesterol-low

See Full Page